With the COVID-19 pandemic resulting in reduced doctor visits and delayed surgeries and procedures, many healthcare stocks have suffered this year. But as things begin…
While President Trump still refuses to concede and control of the Senate is still technically to be determined, a Biden presidency come January 20th appears…
For bullish biotech investors looking for a way to play the sector well into 2021, today’s article highlights an ETF to consider for that purpose,…
From traditional “Big Pharma” stocks that have adopted (or are adopting) a greater focus on biotech to large “pure-play” biotech companies to “emerging” biotech stocks…
From the country’s strategy for tackling COVID-19 to U.S.-China tensions to government regulations, some key changes can be expected under the coming Biden administration. At…
When it comes to treating diseases, the author of today’s article notes “It seems that there is a shift away from treating symptoms with chemical…
For those who missed out on the massive rallies of Tesla and other electric vehicle companies, today’s article highlights another potential multi-bagger opportunity in the…
Amid all the high drama surrounding last week’s elections, a smaller development could have big implications for one biotech startup. As today’s article explains, voters…
The two biotech stocks highlighted in today’s article both made their public market debuts in 2018 – and both have performed very well for investors…
Amid a third-quarter earnings season that has been a mixed bag of beats and misses for drug/biotech companies, today’s article highlights five drug/biotech stocks that…